强化降低胆固醇预防卒中(The Stroke Prevention by Aggressive Reduction in Cholesterol Levels,SPARCL)试验已经证明,对近期有过短暂性脑缺血发作(TIA)或卒中的患者,阿托伐他汀80 mg/d可降低心血管事件和卒中的发生率。哥本哈根大学的学者对入组SPARCL试验的患者行进一步研究后提出,对于颈动脉狭窄的SPARCL亚组患者,阿托伐他汀的疗效更显著。SPARCL试验的入组标准是入院前1～6 The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial has shown that atorvastatin 80 mg / day can be reduced in patients with a recent transient ischemic attack (TIA) or stroke Cardiovascular events and the incidence of stroke. A further study by cohorts of patients at the University of Copenhagen who had been enrolled in the SPARCL trial suggested that atorvastatin is more effective in the SPARCL subgroup of patients with carotid stenosis. The inclusion criteria for the SPARCL trial were 1 to 6 pre-admission